H.C. Wainwright Has Just Reaffirmed $34.0000 Target Price Per Share on Omeros Corp (NASDAQ:OMER) stock, While They’ve Also Reiterated Their “Buy” Rating

May 11, 2018 - By Stephen Andrade

Omeros Corporation (NASDAQ:OMER) Logo

Investors sentiment decreased to 1.3 in Q4 2017. Its down 1.56, from 2.86 in 2017Q3. It worsened, as 14 investors sold Omeros Corporation shares while 29 reduced holdings. 31 funds opened positions while 25 raised stakes. 21.94 million shares or 0.43% less from 22.04 million shares in 2017Q3 were reported.

Washington Tru Retail Bank accumulated 0.01% or 5,143 shares. First Interstate Commercial Bank holds 0.02% or 5,000 shares in its portfolio. Legal & General Gp Plc has 11,299 shares for 0% of their portfolio. 15,273 were accumulated by Teacher Retirement System Of Texas. Hightower Advsr Limited Liability Corporation reported 18,014 shares. State Board Of Administration Of Florida Retirement System holds 0% or 30,737 shares in its portfolio. Swiss State Bank reported 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Credit Suisse Ag holds 53,592 shares. Schwab Charles Management has 215,878 shares. Stifel invested in 342,192 shares or 0.02% of the stock. Adage Prns Grp Llc reported 0.01% in Omeros Corporation (NASDAQ:OMER). Price T Rowe Associates Inc Md holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 10,913 shares. Manufacturers Life Insur The reported 65,197 shares. Tru Department Mb National Bank N A has invested 0.01% of its portfolio in Omeros Corporation (NASDAQ:OMER). Trexquant Lp has invested 0.02% of its portfolio in Omeros Corporation (NASDAQ:OMER).

Since January 3, 2018, it had 0 insider buys, and 2 selling transactions for $1.36 million activity. JACOBSEN MICHAEL A sold 1,020 shares worth $22,899.

Omeros Corp (NASDAQ:OMER) Rating Reaffirmed

In a report revealed to clients and investors on Friday morning, The “Buy” rating of Omeros Corp (NASDAQ:OMER) shares was kept by Analysts at H.C. Wainwright, who now has a $34.0000 target price per share on the stock. H.C. Wainwright’s target price per share would indicate a possible upside of 70.94 % from the last price of the company.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 5 analysts covering Omeros Corp (NASDAQ:OMER), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Omeros Corp has $7500 highest and $25 lowest target. $45.25’s average target is 127.50% above currents $19.89 stock price. Omeros Corp had 14 analyst reports since November 28, 2017 according to SRatingsIntel. H.C. Wainwright maintained the shares of OMER in report on Thursday, January 4 with “Buy” rating. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) on Wednesday, April 4 with “Buy” rating. On Friday, March 23 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by WBB Securities with “Buy” on Monday, March 26. The firm has “Hold” rating by Needham given on Friday, March 2. On Tuesday, January 23 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, December 14 report. On Thursday, April 19 the stock rating was maintained by H.C. Wainwright with “Buy”. Maxim Group maintained the stock with “Buy” rating in Thursday, March 22 report. The firm has “Neutral” rating given on Friday, March 23 by Wedbush.

The stock increased 23.31% or $3.76 during the last trading session, reaching $19.89. About 2.70 million shares traded or 82.08% up from the average. Omeros Corporation (NASDAQ:OMER) has declined 3.39% since May 11, 2017 and is downtrending. It has underperformed by 14.94% the S&P500.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $960.42 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

More notable recent Omeros Corporation (NASDAQ:OMER) news were published by: Seekingalpha.com which released: “Omeros Corporation: Elucidating Formulary Expansion At The VA” on April 13, 2018, also Benzinga.com with their article: “38 Stocks Moving In Friday’s Mid-Day Session” published on May 11, 2018, Seekingalpha.com published: “Omeros’ (OMER) CEO Gregory Demopulos on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018. More interesting news about Omeros Corporation (NASDAQ:OMER) were released by: Seekingalpha.com and their article: “Omeros Corporation: Substantial Value Added To The HSCT-TMA Franchise” published on April 30, 2018 as well as Benzinga.com‘s news article titled: “Stock Performance Review on Biotech Industry — Neptune Technologies & Bioressources, NewLink Genetics, OHR …” with publication date: May 08, 2018.

Omeros Corporation (NASDAQ:OMER) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: